Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 89.27% is 55% below its 2-year average of 197.94%, near the low end of its 2-year range (89.27%–284.87%).
As of the fiscal period ended Wednesday, December 31, 2025. 35.87% below its 12-month average of 139.21%.
Reported quarterly debt to assets ratio; no daily interpolation. Q4 FY2025 (2025-12-31): 89.27%.
DEBT TO ASSETS RATIO
89.27%
DEBT TO ASSETS RATIO AVG TTM
139.21%
DEBT TO ASSETS RATIO AVG 3Y
N/A
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-35.87%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
+99091.45%
vs the sector median at left
Jyong Biotech Ltd. Ordinary Shares
Market Cap
$152.06M
Debt to Assets Ratio
89.27%
TTM Avg
139.21%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$151.58M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$149.19M
Debt to Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$148.36M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$148.02M
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$147.81M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jyong Biotech Ltd. Ordinary Shares (MENS) | $152.06M | 89.27% | 139.21% | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.58M | 0.00% | N/A | N/A | N/A |
| LifeMD, Inc. (LFMDP)vs › | $154.79M | 0.10% | N/A | N/A | N/A |
| Veraxa Biotech Holding AG (VRXA)vs › | $149.19M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $148.97M | 0.60% | N/A | N/A | N/A |
| Neuronetics, Inc. (STIM)vs › | $155.45M | 0.66% | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $148.36M | 0.00% | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $148.02M | 0.06% | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $147.81M | 0.00% | N/A | N/A | N/A |
| Voyager Therapeutics, Inc. (VYGR)vs › | $147.73M | 0.16% | N/A | N/A | N/A |
Debt/Assets
89.3%
Debt/Equity
N/A
Current Ratio
0.45
Interest Coverage
-1.0x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2025-12-31 | 89.27% |
| 2025-09-30 | 89.27% |
| 2025-06-30 | 93.42% |
| 2024-12-31 | 284.87% |
| 2024-09-30 | 284.87% |
| 2024-06-30 | 269.70% |
| 2024-03-31 | 269.70% |
| 2023-12-31 | 202.36% |
